---
title: "Ligand Q2 FY26 adjusted EPS climbs 48% to $2.37; revenue rises 34% to $63.7 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295096102.md"
description: "Ligand Pharmaceuticals reported Q2 FY26 results with adjusted EPS rising 48% to $2.37 and revenue increasing 34% to $63.7 million, driven by a 32% rise in royalties. Non-GAAP net income climbed 59% to $50.78 million. The company holds $1.36 billion in cash following a $700 million convertible notes offering. Ligand reaffirmed its 2026 total revenue guidance of $270-$310 million and raised the low end of its non-GAAP adjusted EPS forecast to approximately $9."
datetime: "2026-08-06T11:09:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295096102.md)
  - [en](https://longbridge.com/en/news/295096102.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295096102.md)
generator: "portal-rs"
---

# Ligand Q2 FY26 adjusted EPS climbs 48% to $2.37; revenue rises 34% to $63.7 million

-   Ligand Pharmaceuticals posted Q2 GAAP net income of $48.51 million, or $2.22 per diluted share, versus $4.85 million, or $0.24, a year earlier. \* Total revenue rose 34% year over year to $63.69 million, driven by royalties of $48.03 million, up 32%. \* Non-GAAP adjusted net income climbed 59% to $50.78 million, lifting adjusted diluted EPS 48% to $2.37. \* Cash, cash equivalents and short-term investments totaled $1.36 billion at June 30, up from $733.52 million at year-end, following a $700 million 0.00% convertible senior notes due 2031 offering. \* Reaffirmed 2026 total revenue guidance of $270 million-$310 million, raising the low end of non-GAAP adjusted EPS to about $9-$9.5 from $8.5-$9.5. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)

## Related News & Research

- [$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296632631.md)
- [Breakout watch: Savvy investors bet millions on royalty-fueled pharma stock](https://longbridge.com/en/news/295793482.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)
- [Plazza posts H1 2026 interim report online](https://longbridge.com/en/news/296736136.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**